Webinar: Beyond PSA: Utility of a urine gene expression assay for early detection of prostate cancer in the primary care setting
Prostate cancer is a leading cause of cancer in men, affecting more than 248,000 in the United States and resulting in 34,000 deaths annually. Most guidelines now support shared decision-making around the question of prostate cancer early detection—but how exactly to do this remains controversial.
The conversations can be confusing, especially during a time when appointments and procedures have been canceled and COVID-19 has upended our normal way of practicing, leaving both patients and physicians scrambling for answers.
PSA remains the gold standard as a first-line screening test, but is limited in terms of specificity, especially among older men. We now have new non-invasive biomarkers available which can help prioritize who needs to see a urologist sooner and determine who should proceed with biopsy, in order to find high-grade, potentially lethal tumors early while minimizing over-diagnosis of low-grade, indolent tumors.
- Review challenges of prostate cancer and importance of early detection
- Discuss benefits and limitations of PSA screening
- Understand how biomarkers can improve decision-making for early detection of prostate cancer in the primary care setting
- Discuss prostate cancer staging and implications for practice